Amgen bets on growth in China

Biotechnology company Amgen is investing U.S. $2.7 billion in the Chinese biotech firm Beigene. The all-cash deal values gives Amgen a 20% stake in BeiGene and going forward, BeiGene will commercialize some of Amgen’s cancer drugs which will be sold in China. The two...